 HMG-CoA reductase inhibitor-induced myopathy rat cyclosporine interaction mechanism studies Recent clinical evidence potential skeletal muscle toxicity therapy HMG-CoA reductase inhibitors HMGRIs man incidence drug-induced skeletal muscle toxicity low monotherapy concomitant drug therapy immunosuppressant CsA certain hypolipidemic agents Sprague-Dawley rat high comparable dosages mg/kg/day similar HMGRIs lovastatin simvastatin pravastatin dose-related increases incidence severity skeletal muscle degeneration Physical signs inappetence decreased activity loss body weight alopecia mortality interaction HMGRIs CsA rat model CsA-induced cholestasis model skeletal muscle toxicity HMGRIs CsA mg/kg/day Doses HMGRIs skeletal muscle toxicity incidence myopathy skeletal muscle degeneration CsA Typical light microscopic changes myofiber necrosis interstitial edema inflammatory infiltration areas acute injury Histochemical characterization muscle lesion type fibers glycolytic white fibers sensitive toxicity prolonged administration types Results pharmacokinetic studies rats various HMGRIs CsA coadministration CsA disposition compounds systemic exposure increased area plasma drug concentration time curve-AUC consequent skeletal muscle drug levels Evaluation potential interaction HMGRI lovastatin CsA level hepatic microsomal metabolism CsA metabolism lovastatin isolated microsomes female rats light findings HMGRI-induced myopathy class effect rat CsA result altered clearance resultant tissue exposure Cholestasis CsA HMGRIs basis decreased elimination resultant systemic exposure toxicity fiber-selective impaired skeletal muscle energy metabolism